Abstract:Charcot-Marie-Tooth X1 (CMTX1) disease is an inherited
peripheral
neuropathy that arises from loss-of-function mutations in the protein
connexin 32 (Cx32). CMTX1 currently lacks a pharmacologic approach
toward disease management, and we have previously shown that modulating
the expression of molecular chaperones using novologue therapy may
provide a viable disease-modifying approach to treat metabolic and
demyelinating neuropathies. Cemdomespib is an orally bioavailable
novologue that manifests neuroprotective… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.